Creating cellular medicines from red blood cells
Rubius Therapeutics is genetically engineering red blood cell therapeutics, or RCTs, to treat a range of diseases. These RCTs are capable of targeting cancer through activating immunity, treating auto-immune diseases through self-antigen tolerance induction, and combating rare enzyme deficiencies by introducing therapeutic enzymes that are cellularly shielded.
Challenges
| Collaborating with inaccessible data | Manual record keeping systems that housed all experimental data – including donor metadata, DNA stock, and prototype protein expression – were disorganized and cluttered, hindering cross-team collaboration. |
|---|---|
| Inefficient request fulfillment | Legacy request management protocols were inefficient and required scientists and managers to search through scattered, disparate records on cell cultures and quality control assays. |
| Difficulty tracking projects | Engineering processes were out of sync and difficult to track as a result of decentralized systems of information storage and unreliable reporting on project progress. |
Outcomes
| Cross-team collaboration with complete experimental context | Rubius stores, shares, and interlinks all the experimental data of their samples, vectors, and engineered red blood cells in Benchling. Now, Rubius effortlessly navigates from sequences to prototype backgrounds and experimental conditions. |
|---|---|
| Insightful request management | Rubius now streamlines their request fulfillment process, ultimately using this information to track experiment status and forecast needs in real-time. |
| Centralized project management | With Benchling Workflows, Rubius structures, executes on, and optimizes their cell engineering processes from DNA production to cell construction. |
